Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease
Geoffrey C. Nguyen(Johns Hopkins Medicine), Gil Melmed, Karen Boland(Beaumont Hospital), Waqqas Afif, Gilaad G. Kaplan(University of Calgary), Reena Khanna(University of Toronto), Laura E. Targownik(University of Manitoba), Tanya Chawla(University of Toronto), Sanjay K. Murthy(University of Ottawa), Brian Bressler(University of British Columbia), Luís Guimarães(University of Toronto), Jennifer Jones(Dalhousie University), Cynthia H. Seow(University of Calgary), Sharyle Fowler(Massachusetts General Hospital), Smita Halder(McMaster University), Aida Fernandes(Crohn's and Colitis Canada), Adam V. Weizman(Mount Sinai Hospital), Joannie Ruel(Centre Hospitalier Universitaire de Sherbrooke), Sherif Saleh(Mount Sinai Hospital), Vivian Huang
Cited by 32
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
|Gastroenterology|2020|692
Genome-wide association identifies multiple ulcerative colitis susceptibility loci
|Nature Genetics|2010|680